1.19
-0.17(-12.55%)
Currency In USD
| Previous Close | 1.36 |
| Open | 1.35 |
| Day High | 1.37 |
| Day Low | 1.18 |
| 52-Week High | 8.37 |
| 52-Week Low | 1.18 |
| Volume | 240,670 |
| Average Volume | 325,568 |
| Market Cap | 57.97M |
| PE | -0.73 |
| EPS | -1.62 |
| Moving Average 50 Days | 1.71 |
| Moving Average 200 Days | 2.92 |
| Change | -0.17 |
Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025
GlobeNewswire Inc.
Feb 24, 2025 12:00 PM GMT
BURLINGTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering pattern breaking approaches for the treatment of obesity and type 2 diabetes (T2D), tod
Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025
GlobeNewswire Inc.
Jan 31, 2025 1:01 PM GMT
Prioritizing Revita’s clinical development on weight maintenance post-GLP-1 withdrawal in response to significant patient and physician demand in ongoing REMAIN-1 pivotal study; anticipate midpoint data analysis in Q2 2025 and full pivotal study enro
Fractyl Health Announces Positive Initial Clinical Results Demonstrating Weight Maintenance Following GLP-1 Discontinuation and Revita Procedure in First Patient of the REVEAL-1 Cohort
GlobeNewswire Inc.
Jan 13, 2025 12:00 PM GMT
Company also announces strong enrollment progress for REMAIN-1 weight maintenance pivotal study High demand from patients and physicians indicates significant interest in REMAIN-1 study and GLP-1 discontinuation; mid-point analysis on-track and an